BRWA
IMDX

B. Riley Wealth Advisors’s Insight Molecular Diagnostics IMDX Stock Holding History

B. Riley Wealth Advisors’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-895
Closed -$14K – 1562
2022
Q3 		$14K Buy
+895
New +$15.5K ﹤0.01% 1428

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

B. Riley Wealth Advisors's IMDX Position: Q4 2022 in Review

B. Riley Wealth Advisors sold out of Insight Molecular Diagnostics (IMDX) in Q4 2022, closing a stake of 895 shares — an estimated $14K sold.

B. Riley Wealth Advisors first reported a position in IMDX in Q3 2022 and held it in 1 quarter. The position peaked at $14K in Q3 2022. 58 funds tracked by Wall St. Rank hold IMDX as of Q4 2022.

  • B. Riley Wealth Advisors reported no remaining Insight Molecular Diagnostics position as of Q4 2022 after selling out during the quarter.
  • B. Riley Wealth Advisors sold 895 Insight Molecular Diagnostics shares in Q4 2022, an estimated $14K.
  • B. Riley Wealth Advisors first reported a position in Insight Molecular Diagnostics in Q3 2022 and held it in 1 quarter.
  • B. Riley Wealth Advisors's Insight Molecular Diagnostics position peaked at $14K in Q3 2022.
  • 58 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q4 2022.

Based on B. Riley Wealth Advisors's 13F filing for Q4 2022, filed 21 Feb 2023.